Valuation: Profound Medical Corp.

Market Cap 374M 268M 232M 217M 199M 25.56B 380M 2.54B 996M 12.82B 1.01B 986M 42.36B P/E 2026 *
-8.98x
P/E 2027 * -13x
Enterprise Value 374M 268M 232M 217M 199M 25.56B 380M 2.54B 996M 12.82B 1.01B 986M 42.36B EV / Sales 2026 *
10.3x
EV / Sales 2027 * 6.29x
Free-Float
95.42%
Yield 2026 *
-
Yield 2027 * -
1 day-7.21%
1 week-0.77%
Current month-0.77%
1 month-2.65%
3 months+5.64%
6 months+17.45%
Current year-4.36%
1 week 9.76
Extreme 9.76
11.98
1 month 9.31
Extreme 9.31
11.98
Current year 6.52
Extreme 6.52
12.4
1 year 5.23
Extreme 5.23
12.4
3 years 5.23
Extreme 5.23
16
5 years 4.21
Extreme 4.21
20.78
10 years 4.21
Extreme 4.21
36.73
Manager TitleAgeSince
Chief Executive Officer 71 2016-08-14
President 44 2024-11-06
Director of Finance/CFO 58 2022-03-02
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 2018-06-13
Director/Board Member 79 2018-06-13
Date Insider Type Main position Quantity % Market Cap.
6/24/26 Option

Director

2,016 0.0055%
6/17/26 Option

Chairperson

11,618 0.0320%
12/24/25 Buy

Executive/Senior Manager

13,908 0.0461%
Change 5-day change 1-year change 3-year change Capi.($)
-7.21%-0.77%+32.90%-20.16% 269M
+2.41%+3.43%+30.62%+7.65% 220B
+2.39%+5.02%+3.16%-19.90% 144B
+1.36%+7.21%-19.37%+22.50% 134B
+0.02%+5.52%-52.11%-2.80% 71.46B
+0.45%+4.24%+15.13%+12.37% 51.71B
+1.05%+7.19%-14.42%-19.02% 50.84B
+3.28%+5.49%+28.07%+15.38% 41.23B
+1.79%+7.83%+46.35%+40.43% 39.95B
+2.08%+5.51%+0.94%-5.05% 32.42B
Average +0.76%+4.92%+7.13%+3.14% 78.53B
Weighted average by Cap. +1.79%+5.17%+5.05%+4.30%

Financials

2026 *2027 *
Net sales 36.22M 25.97M 22.49M 20.96M 19.26M 2.47B 36.8M 246M 96.4M 1.24B 97.58M 95.46M 4.1B 59.47M 42.62M 36.92M 34.4M 31.62M 4.06B 60.41M 404M 158M 2.04B 160M 157M 6.73B
Net income -41.93M -30.06M -26.03M -24.26M -22.29M -2.86B -42.6M -285M -112M -1.44B -113M -110M -4.75B -29.22M -20.94M -18.14M -16.9M -15.53M -2B -29.68M -199M -77.75M -1B -78.7M -76.99M -3.31B
Net Debt - -
Logo Profound Medical Corp.
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
162
Date Price Change Volume
26-08-07 $10.30 -7.21% 26,714
26-08-06 $11.10 -0.98% 9,245
26-08-05 $11.21 -4.68% 10,390
26-08-04 $11.76 +13.29% 41,628
26-07-31 $10.38 +1.17% 8,858
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
10.30
Average target price
-

Quarterly revenue - Rate of surprise